# PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

> **NCT04517864** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 71 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** PF-06651600
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04517864
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-15
- **Primary completion:** 2022-01-04
- **Final completion:** 2024-05-07
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** For business reasons
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517864, "PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04517864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*